Anti-nociceptive effect of thalidomide on zymosan-induced experimental articular incapacitation

European Journal of Pharmacology

Volumn 536, Issue 3, 2006, Pages 309-317

  Vale, Mariana L ^a   Cunha, Fernando Q ^b   Brito, Gerly A C ^a   Benevides, Verônica M ^a   Ferreira, Sérgio H ^b   Poole, Stephen ^c   Ribeiro, Ronaldo A ^a  

^a FEDERAL UNIVERSITY OF CEARÁ   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

Author keywords

Arthritis; Hyperalgesia; Thalidomide; Tumor necrosis factor; Zymosan

Indexed keywords

CYTOKINE INDUCED NEUTROPHIL CHEMOATTRACTANT; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; NALOXONE; OPIATE ANTAGONIST; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; ZYMOSAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINOCICEPTION; ARTHROPATHY; ARTICLE; DOSE RESPONSE; DRUG EFFECT; EXUDATE; HYPERALGESIA; IMMUNOHISTOCHEMISTRY; KNEE; MALE; NOCICEPTION; NONHUMAN; PRIORITY JOURNAL; RAT; SYNOVIUM;

ANALGESICS; ANIMALS; ARTHRALGIA; ARTHRITIS, EXPERIMENTAL; CHEMOKINES, CXC; EXUDATES AND TRANSUDATES; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS, INTRAPERITONEAL; INTERLEUKIN-1; INTERLEUKIN-6; KNEE JOINT; MALE; NALOXONE; NARCOTIC ANTAGONISTS; RATS; RATS, WISTAR; SYNOVIAL MEMBRANE; THALIDOMIDE; TUMOR NECROSIS FACTOR-ALPHA; ZYMOSAN;

EID: 33646024266     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2006.02.051     Document Type: Article

References (71)

1. Anaya J.M., and Espinoza L.R. Phosphodiesterase inhibitor pentoxifylline-an antiinflammatory/immunomodulatory drug potentially useful in some rheumatic diseases. Journal of Rheumatology 22 (1995) 595-599
2. Bariol C., Meagher A.P., Vickers C.R., Byrnes D.J., Edwards P.D., Hing M., Wettstein A.R., and Field A. Early studies on the safety and efficacy of thalidomide for symptomatic inflammatory bowel disease. Journal of Gastroenterology and Hepatology 17 (2002) 135-139
3. Breedveld F.C., Emery P., Keystone E., Patel K., Furst D.E., Kalden J.R., St Clair E.W., Weisman M., Smolen J., Lipsky P.E., and Maini R.N. Infliximab in active early rheumatoid arthritis. Annals of the Rheumatic Diseases 63 (2004) 149-155
4. Brennan F.M., Chantry D., Jackson A., Maini R., and Feldmann M. Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 2 (1989) 244-247
5. Corsini E., and Galli C.L. Cytokines and irritant contact dermatitis. Toxicology Letters 102-103 (1998) 277-282
6. Culy C.R., and Keating G.M. Etanercept-an updated review of its use in rheumatoid arthritis, psoriatic arthritis and juvenile rheumatoid arthritis. Drugs 62 (2002) 2493-2537
7. Cunha F.Q., Lorenzetti B.B., Poole S., and Ferreira S.H. Interleukin-8 as a mediator of sympathetic pain. British Journal of Pharmacology 104 (1991) 765-767
8. Cunha F.Q., Poole S., Lorenzetti B.B., and Ferreira S.H. The pivotal role of tumour necrosis factor alpha in the development of inflammatory hyperalgesia. British Journal of Pharmacology 107 (1992) 660-664
9. Cunha F.Q., Boukili M.A., da Motta J.I., Vargaftig B.B., and Ferreira S.H. Blockade by fenspiride of endotoxin-induced neutrophil migration in the rat. European Journal of Pharmacology 238 (1993) 47-52
10. Cunha F.Q., Poole S., Lorenzetti B.B., Veiga F.H., and Ferreira S.H. Cytokine-mediated inflammatory hyperalgesia limited by interleukin-4. British Journal of Pharmacology 126 (1999) 45-50
11. Cunha J.M., Cunha F.Q., Poole S., and Ferreira S.H. Cytokine-mediated inflammatory hyperalgesia limited by interleukin-1 receptor antagonist. British Journal of Pharmacology 130 (2000) 1418-1424
12. Cunha T.M., Verri W.A., Silva J.S., Poole S., Cunha F.Q., and Ferreira S.H. A cascade of cytokines mediates mechanical inflammatory hypernociception in mice. Proceedings of the National Academy of Sciences of the United States of America 102 (2005) 1755-1760
13. da S Rocha J.C., Peixoto M.E., Jancar S., Cunha F.Q., Ribeiro R.A., and Rocha F.A. Dual effect of nitric oxide in articular inflammatory pain in zymosan-induced arthritis in rats. British Journal of Pharmacology 136 (2002) 588-596
14. da Rocha F.A.C., Teixeira M.M., Rocha J.C.D.S., Claudia V., Girao C., Bezerra M.M., Ribeiro R.D.A., and Cunha F.D.Q. Blockade of leukotriene B-4 prevents articular incapacitation in rat zymosan-induced arthritis. European Journal of Pharmacology 497 (2004) 81-86
15. De Jongh R.F., Vissers K.C., Meert T.F., Booij L.H., De Deyne C.S., and Heylen R.J. The role of interleukin-6 in nociception and pain. Anesthesia and Analgesia 96 (2003) 1096-1103 table
16. Djeu J.Y., Serbousek D., and Blanchard D.K. Release of tumor necrosis factor by human polymorphonuclear leukocytes. Blood 76 (1990) 1405-1409
17. Eastgate J.A., Symons J.A., Wood N.C., Grinlinton F.M., di Giovine F.S., and Duff G.W. Correlation of plasma interleukin 1 levels with disease activity in rheumatoid arthritis. Lancet 2 (1988) 706-709
18. Ehrenpreis E.D., Kane S.V., Cohen L.B., Cohen R.D., and Hanauer S.B. Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial. Gastroenterology 117 (1999) 1271-1277
19. Elliott M.J., Maini R.N., Feldmann M., Longfox A., Charles P., Bijl H., and Woody J.N. Repeated therapy with monoclonal-antibody to tumor-necrosis-factor-alpha (Ca2) in patients with rheumatoid-arthritis. Lancet 344 (1994) 1125-1127
20. Feldmann M., Brennan F.M., and Maini R.N. Role of cytokines in rheumatoid arthritis. Annual Review of Immunology 14 (1996) 397-440
21. 2+ dependent process. Prostaglandins 18 (1979) 179-190
22. Ferreira S.H., Lorenzetti B.B., Bristow A.F., and Poole S. Interleukin-1-beta as a potent hyperalgesic agent antagonized by a tripeptide analog. Nature 334 (1988) 698-701
23. Fujisawa H., Wang B.H., Kondo S., Shivji G.M., and Sauder D.N. Costimulation with ultraviolet B and interleukin-1 alpha dramatically increase tumor necrosis factor-alpha production in human dermal fibroblasts. Journal of Interferon and Cytokine Research 17 (1997) 307-313
24. Furst D.E., Breedveld F.C., Burmester G.R., Crofford L., Emery P., Feldman M., Kalden J.R., Kavanaugh A., Keystone E., Lipsky E.P., Maini R.N., Moreland L., Smolen J.S., Van de Putte L., Smolen J.S., Van de Putte L., Vischer T., Weinblatt M., and Weissman M. Access to disease modifying treatments for rheumatoid arthritis patients. Annals of the Rheumatic Diseases 58 (1999) 129-130
25. Furst D.E., Schiff M.H., Fleischmann R.M., Strand V., Birbara C.A., Compagnone D., Fischkoff S.A., and Chartash E.K. Adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). Journal of Rheumatology 30 (2003) 2563-2571
26. Gordon J.R., and Galli S.J. Release of both preformed and newly synthesized tumor-necrosis-factor-alpha (Tnf-Alpha)/cachectin by mouse mast-cells stimulated via the Fc-Epsilon-Ri-a mechanism for the sustained action of mast-cell derived Tnf-alpha during Ige-dependent biological responses. Journal of Experimental Medicine 174 (1991) 103-107
27. Gutierrez-Rodriguez O., Starusta-Bacal P., and Gutierrez-Montes O. Treatment of refractory rheumatoid arthritis-the thalidomide experience. Journal of Rheumatology 16 (1989) 158-163
28. Hamuryudan V., Mat C., Saip S., Ozyazgan Y., Siva A., Yurdakul S., Zwingenberger K., and Yazici H. Thalidomide in the treatment of the mucocutaneous lesions of the Behcet syndrome-a randomized, double-blind, placebo-controlled trial. Annals of Internal Medicine 128 (1998) 443+
29. Harris E.D. Mechanisms of disease-rheumatoid-arthritis-pathophysiology and implications for therapy. New England Journal of Medicine 322 (1990) 1277-1289
30. Hsu S.M., Raine L., and Fanger H. The use of antiavidin antibody and avidin-biotin-peroxidase complex in immunoperoxidase techniques. American Journal of Clinical Pathology 75 (1981) 816-821
31. Huizinga T.W.J., Dijkmans B.A.C., vanderVelde E.A., Kraan T.C.T.M., Verweij C.L., and Breedveld F.C. An open study of pentoxyfylline and thalidomide as adjuvant therapy in the treatment of rheumatoid arthritis. Annals of the Rheumatic Diseases 55 (1996) 833-836
32. Idogawa H., Imamura A., Onda M., Umemura T., and Ohashi M. Progression of articular destruction and the production of tumour necrosis factor-alpha in antigen-induced arthritis in rabbits. Scandinavian Journal of Immunology 46 (1997) 572-580
33. Inglis J.J., Nissim A., Lees D.M., Hunt S.P., Chernajovsky Y., and Kidd B.L. The differential contribution of tumour necrosis factor to thermal and mechanical hyperalgesia during chronic inflammation. Arthritis Research and Therapy 7 (2005) R807-R816
34. Junger H., and Sorkin L.S. Nociceptive and inflammatory effects of subcutaneous TNF alpha. Pain 85 (2000) 145-151
35. Knop J., Bonsmann G., Happle R., Ludolph A., Matz D.R., Mifsud E.J., and Macher E. Thalidomide in the treatment of 60 cases of chronic discoid lupus-erythematosus. British Journal of Dermatology 108 (1983) 461-466
36. Lorenzetti B.B., Poole S., Veiga F.H., Cunha F.Q., and Ferreira S.H. Cytokine-mediated inflammatory hyperalgesia limited by interleukin-13. European Cytokine Network 12 (2001) 260-267
37. Lorenzetti B.B., Veiga F.H., Canetti C.A., Poole S., Cunha F.Q., and Ferreira S.H. Cytokine-induced neutrophil chemoattractant(1) (CINC-1) mediates the sympathetic component of inflammatory mechanical hypersensitivity in rats. European Cytokine Network 13 (2002) 456-461
38. Matthews N. Tumour-necrosis factor from the rabbit. V. Synthesis in vitro by mononuclear phagocytes from various tissues of normal and BCG-injected rabbits. British Journal of Cancer 44 (1981) 418-424
39. Millan M.J. The induction of pain: an integrative review. Progress in Neurobiology 57 (1999) 1-164
40. Moreira A.L., Sampaio E.P., Zmuidzinas A., Frindt P., Smith K.A., and Kaplan G. Thalidomide exerts its inhibitory-action on tumor-necrosis-factor-alpha by enhancing messenger-RNA degradation. Journal of Experimental Medicine 177 (1993) 1675-1680
41. Moreira A.L., Wang J., Sarno E.N., and Kaplan G. Thalidomide protects mice against lipopolyssacharide-induced shock. Brazilian Journal of Medical and Biological Research 30 (1997) 1199-1207
42. Nakamura M., and Ferreira S.H. A peripheral sympathetic component in inflammatory hyperalgesia. European Journal of Pharmacology 135 (1987) 145-153
43. Neale M.L., Williams B.D., and Matthews N. Tumour necrosis factor activity in joint fluids from rheumatoid arthritis patients. British Journal of Rheumatology 28 (1989) 104-108
44. Obreja O., Schmelz M., Poole S., and Kress M. Interleukin-6 in combination with its soluble interleukin-6 receptor sensitises rat skin nociceptors to heat, in vivo. Pain 96 (2002) 57-62
45. Oliver S.J., Moreira A., and Kaplan G. Immune stimulation in scleroderma patients treated with thalidomide. Clinical Immunology 97 (2000) 109-120
46. Opree A., and Kress M. Involvement of the proinflammatory cytokines tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-6 but not interleukin-8 in the development of heat hyperalgesia: effects on heat-evoked calcitonin gene-related peptide release from rat skin. Journal of Neuroscience 20 (2000) 6289-6293
47. Perkins M.N., and Kelly D. Interleukin-1-beta induced Desarg(9)Bradykinin-mediated thermal hyperalgesia in the rat. Neuropharmacology 33 (1994) 657-660
48. Poole S., Cunha F.Q., Selkirk S., Lorenzetti B.B., and Ferreira S.H. Cytokine-mediated inflammatory hyperalgesia limited by interleukin-10. British Journal of Pharmacology 115 (1995) 684-688
49. Present D.H., Rutgeerts P., Targan S., Hanauer S.B., Mayer L., Van Hogezand R.A., Podolsky D.K., Sands B.E., Braakman T., DeWoody K.L., Schaible T.F., and Van Deventer S.J.H. Infliximab for the treatment of fistulas in patients with Crohn's disease. New England Journal of Medicine 340 (1999) 1398-1405
50. Ribeiro R.A., Vale M.L., Thomazzi S.M., Paschoalato A.B.P., Poole S., Ferreira S.H., and Cunha F.Q. Involvement of resident macrophages and mast cells in the writhing nociceptive response induced by zymosan and acetic acid in mice. European Journal of Pharmacology 387 (2000) 111-118
51. Ribeiro R.A., Vale M.L., Ferreira S.H., and Cunha F.Q. Analgesic effect of thalidomide on inflammatory pain. European Journal of Pharmacology 391 (2000) 97-103
52. Rocha F.A.C., Aragao A.G.M., Oliveira R.C., Pompeu M.M.L., Vale M.R., and Ribeiro R.A. Periarthritis promotes gait disturbance in zymosan-induced arthritis in rats. Inflammation Research 48 (1999) 485-490
53. Sachs D., Cunha F.Q., Poole S., and Ferreira S.H. Tumour necrosis factor-alpha, interleukin-1 beta and interleukin-8 induce persistent mechanical nociceptor hypersensitivity. Pain 96 (2002) 89-97
54. Sampaio E.P., Sarno E.N., Galilly R., Cohn Z.A., and Kaplan G. Thalidomide selectively inhibits tumor-necrosis-factor-alpha production by stimulated human monocytes. Journal of Experimental Medicine 173 (1991) 699-703
55. Sampaio E.P., Kaplan G., Miranda A., Nery J.A.C., Miguel C.P., Viana S.M., and Sarno E.N. The influence of thalidomide on the clinical and immunological manifestation of erythema-nodosum leprosum. Journal of Infectious Diseases 168 (1993) 408-414
56. Schafers M., Sorkin L.S., Geis C., and Shubayev V.I. Spinal nerve ligation induces transient upregulation of tumor necrosis factor receptors 1 and 2 in injured and adjacent uninjured dorsal root ganglia in the rat. Neuroscience Letters 347 (2003) 179-182
57. Schaible H.G., Ebersberger A., and Von Banchet G.S. Mechanisms of pain in arthritis. Neuroendocrine Immune Basis of the Rheumatic Diseases II, Proceedings 966 (2002) 343-354
58. Sheskin J. Thalidomide in the treatment of lepra reactions. Clinical Pharmacology and Therapeutics 40 (1965) 303-306
59. Sommer C., Marziniak M., and Myers R.R. The effect of thalidomide treatment on vascular pathology and hyperalgesia caused by chronic constriction injury of rat nerve. Pain 74 (1998) 83-91
60. Stevens R.J., Andujar C., Edwards C.J., Ames P.R.J., Barwick A.R., Khamashta M.A., and Hughes G.R.V. Thalidomide in the treatment of the cutaneous manifestations of lupus erythematosus: experience in sixteen consecutive patients. British Journal of Rheumatology 36 (1997) 353-359
61. Tonussi C.R., and Ferreira S.H. Rat knee-joint carrageenin incapacitation test: an objective screen for central and peripheral analgesics. Pain 48 (1992) 421-427
62. Tonussi C.R., and Ferreira S.H. Tumour necrosis factor-alpha mediates carrageenin-induced knee-joint incapacitation and also triggers overt nociception in previously inflamed rat knee-joints. Pain 82 (1999) 81-87
63. Vale M.L., Marques J.B., Moreira C.A., Rocha F.A.C., Ferreira S.H., Poole S., Cunha F.Q., and Ribeiro R.A. Anti-nociceptive effects of interleukin-4, -10, and -13 on the writhing response in mice and zymosan-induced knee joint incapacitation in rats. Journal of Pharmacology and Experimental Therapeutics 304 (2003) 102-108
64. Vale M.L., Benevides V.M., Sachs D., Brito G.A.C., da Rocha F.A.C., Poole S., Ferreira S.H., Cunha F.Q., and Ribeiro R.A. Antihyperalgesic effect of pentoxifylline on experimental inflammatory pain. British Journal of Pharmacology 143 (2004) 833-844
65. Vandenbroek H. Treatment of prurigo nodularis with thalidomide. Archives of Dermatology 116 (1980) 571-572
66. Vogelsang G.B., Farmer E.R., Hess A.D., Altamonte V., Beschorner W.E., Jabs D.A., Corio R.L., Levin L.S., Colvin O.M., Wingard J.R., and Santos G.W. Thalidomide for the treatment of chronic graft-versus-host disease. New England Journal of Medicine 326 (1992) 1055-1058
67. Wagner R., Janjigian M., and Myers R.R. Anti-inflammatory interleukin-10 therapy in CCI neuropathy decreases thermal hyperalgesia, macrophage recruitment, and endoneurial TNF-alpha expression. Pain 74 (1998) 35-42
68. Wei J.C.C., Chan T.W., Lin H.S., Huang F., and Chou C.T. Thalidomide for severe refractory ankylosing spondylitis: a 6-month open-label trial. Journal of Rheumatology 30 (2003) 2627-2631
69. Williams R.O., Feldmann M., and Maini R.N. Antitumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proceedings of the National Academy of Sciences of the United States of America 89 (1992) 9784-9788
70. Woolf C.J., Allchorne A., SafiehGarabedian B., and Poole S. Cytokines, nerve growth factor and inflammatory hyperalgesia: the contribution of tumour necrosis factor alpha. British Journal of Pharmacology 121 (1997) 417-424
71. Youle M., Clarbour J., Farthing C., Connolly M., Hawkins D., Staughton R., and Gazzard B. Treatment of resistant aphthous ulceration with thalidomide in patients positive for HIV antibody. British Medical Journal 298 (1989) 432